Literature DB >> 32571633

Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.

Virgilio Galvis1, Francesca Romana Spinelli2, Alejandro Tello3, Claudia L Sossa4, Juan D Higuera4, Edgar D Gómez4, Sergio E Serrano5, Paul A Camacho4, Federico G Velez6.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32571633      PMCID： PMC7261447          DOI： 10.1016/j.arbres.2020.05.008

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN： 0300-2896            Impact factor:   4.872


× No keyword cloud information.
  14 in total

1.  To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.

Authors:  Francesca Romana Spinelli; Fulvia Ceccarelli; Manuela Di Franco; Fabrizio Conti
Journal:  Ann Rheum Dis       Date:  2020-04-02       Impact factor: 19.103

2.  Covid-19: four fifths of cases are asymptomatic, China figures indicate.

Authors:  Michael Day
Journal:  BMJ       Date:  2020-04-02

3.  Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine.

Authors:  J Simon Bell; John A Bell; Darren J Creek
Journal:  Aust J Gen Pract       Date:  2020-04-08

Review 4.  Emerging prophylaxis strategies against COVID-19.

Authors:  Sumita Agrawal; Akhil Dhanesh Goel; Nitesh Gupta
Journal:  Monaldi Arch Chest Dis       Date:  2020-03-30

5.  Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China.

Authors:  An Pan; Li Liu; Chaolong Wang; Huan Guo; Xingjie Hao; Qi Wang; Jiao Huang; Na He; Hongjie Yu; Xihong Lin; Sheng Wei; Tangchun Wu
Journal:  JAMA       Date:  2020-05-19       Impact factor: 56.272

6.  Macular toxicity after short-term hydroxychloroquine therapy.

Authors:  Isil Pasaoglu; Funda E Onmez
Journal:  Indian J Ophthalmol       Date:  2019-02       Impact factor: 1.848

7.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Authors:  Jasper Fuk-Woo Chan; Shuofeng Yuan; Kin-Hang Kok; Kelvin Kai-Wang To; Hin Chu; Jin Yang; Fanfan Xing; Jieling Liu; Cyril Chik-Yan Yip; Rosana Wing-Shan Poon; Hoi-Wah Tsoi; Simon Kam-Fai Lo; Kwok-Hung Chan; Vincent Kwok-Man Poon; Wan-Mui Chan; Jonathan Daniel Ip; Jian-Piao Cai; Vincent Chi-Chung Cheng; Honglin Chen; Christopher Kim-Ming Hui; Kwok-Yung Yuen
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

9.  New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Authors:  Christian A Devaux; Jean-Marc Rolain; Philippe Colson; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-12       Impact factor: 5.283

10.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.